{"title":"胡芦巴对痛经严重程度的影响:系统回顾与元分析》。","authors":"Robab Hassanzadeh, Fatemeh Shabani, Maryam Montazeri, Mojgan Mirghafourvand","doi":"10.2174/2589977515666230818092814","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dysmenorrhea is the most common periodic pain, which affects more than 50% of women with regular menstruation. Fenugreek is one of the medicinal plants with analgesic properties. This study aimed to determine the effect of fenugreek application in the severity of dysmenorrhea and its side effects in women with dysmenorrhea. PICO: Population: women with dysmenorrhea; Intervention: fenugreek; Comparison: control groups; and Outcome: reduction in the severity of dysmenorrhea and its side effects.</p><p><strong>Methods: </strong>English database (PubMed, Cochrane Library, Scopus, and Web of Science) and Persian database [SID (Scientific Information Database) and Magiran] were used for research until February 11, 2023, using the keywords \"Dysmenorrhea [Mesh],\" \"Foenum [Mesh],\" \"fenugreek [Mesh],\" and \"Trigonella [Mesh].\" The reference list of the selected articles was also checked. The quality assessment was conducted through the Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0. The RevMan 5.3 software was used to analyze and report the data of the entered studies. Meta-analysis results were reported with the standardized mean difference (95% confidence interval). A subgroup analysis was performed based on the type of control groups. The quality of evidence was assessed using the GRADE approach.</p><p><strong>Results: </strong>After removing duplicates and ineligible cases, four articles were included in the systematic review out of the 1526 records obtained. The results showed that the pain intensity caused by primary dysmenorrhea decreased with fenugreek compared to placebo (pooled result SMD: -2.21; 95% CI: -3.26 to -1.17; Z: 4.17; p <0.001). There was no significant difference between fenugreek with mefenamic acid (SMD: 0.05; 95% CI: -0.57 to 0.67; Z: 0.17; p = 0.86) and fenugreek with Chandrasura churna (SMD: 0.06; 95% CI: -0.56 to 0.68; Z: 0.19; p = 0.85). Bias, in terms of incomplete outcome data and selective reporting, was low risk in all studies, and the available evidence was low quality according to the GRADE approach.</p><p><strong>Conclusion: </strong>The results showed that the effect of fenugreek on pain intensity in dysmenorrhea is highly uncertain. The true effect is likely to be substantially different from the estimate of effect. Regarding the importance of the health and quality of life of women of reproductive age and the low quality of evidence of the studies, clinical trials with stronger methodology are suggested in this field.</p>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":"219-227"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Fenugreek on the Severity of Dysmenorrhea: A Systematic Review and Meta-analysis.\",\"authors\":\"Robab Hassanzadeh, Fatemeh Shabani, Maryam Montazeri, Mojgan Mirghafourvand\",\"doi\":\"10.2174/2589977515666230818092814\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dysmenorrhea is the most common periodic pain, which affects more than 50% of women with regular menstruation. Fenugreek is one of the medicinal plants with analgesic properties. This study aimed to determine the effect of fenugreek application in the severity of dysmenorrhea and its side effects in women with dysmenorrhea. PICO: Population: women with dysmenorrhea; Intervention: fenugreek; Comparison: control groups; and Outcome: reduction in the severity of dysmenorrhea and its side effects.</p><p><strong>Methods: </strong>English database (PubMed, Cochrane Library, Scopus, and Web of Science) and Persian database [SID (Scientific Information Database) and Magiran] were used for research until February 11, 2023, using the keywords \\\"Dysmenorrhea [Mesh],\\\" \\\"Foenum [Mesh],\\\" \\\"fenugreek [Mesh],\\\" and \\\"Trigonella [Mesh].\\\" The reference list of the selected articles was also checked. The quality assessment was conducted through the Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0. The RevMan 5.3 software was used to analyze and report the data of the entered studies. Meta-analysis results were reported with the standardized mean difference (95% confidence interval). A subgroup analysis was performed based on the type of control groups. The quality of evidence was assessed using the GRADE approach.</p><p><strong>Results: </strong>After removing duplicates and ineligible cases, four articles were included in the systematic review out of the 1526 records obtained. The results showed that the pain intensity caused by primary dysmenorrhea decreased with fenugreek compared to placebo (pooled result SMD: -2.21; 95% CI: -3.26 to -1.17; Z: 4.17; p <0.001). There was no significant difference between fenugreek with mefenamic acid (SMD: 0.05; 95% CI: -0.57 to 0.67; Z: 0.17; p = 0.86) and fenugreek with Chandrasura churna (SMD: 0.06; 95% CI: -0.56 to 0.68; Z: 0.19; p = 0.85). Bias, in terms of incomplete outcome data and selective reporting, was low risk in all studies, and the available evidence was low quality according to the GRADE approach.</p><p><strong>Conclusion: </strong>The results showed that the effect of fenugreek on pain intensity in dysmenorrhea is highly uncertain. The true effect is likely to be substantially different from the estimate of effect. Regarding the importance of the health and quality of life of women of reproductive age and the low quality of evidence of the studies, clinical trials with stronger methodology are suggested in this field.</p>\",\"PeriodicalId\":37008,\"journal\":{\"name\":\"Current Drug Research Reviews\",\"volume\":\" \",\"pages\":\"219-227\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Research Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2589977515666230818092814\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2589977515666230818092814","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
导言痛经是最常见的周期性疼痛,影响着 50%以上月经规律的妇女。葫芦巴是一种具有镇痛作用的药用植物。本研究旨在确定使用葫芦巴对痛经妇女的痛经严重程度及其副作用的影响。PICO:人群:痛经妇女;干预:葫芦巴;比较:对照组;结果:减轻痛经的严重程度及其副作用:使用英文数据库(PubMed、Cochrane Library、Scopus 和 Web of Science)和波斯文数据库[SID(科学信息数据库)和 Magiran]进行研究,关键词为 "Dysmenorrhea [Mesh]"、"Foenum [Mesh]"、"fenugreek [Mesh]"和 "Trigonella [Mesh]",直至 2023 年 2 月 11 日。此外,还检查了所选文章的参考文献目录。质量评估通过 Cochrane Handbook for Systematic Reviews of Interventions 5.2.0 版本进行。RevMan 5.3 软件来分析和报告输入的研究数据。元分析结果以标准化平均差(95% 置信区间)进行报告。根据对照组的类型进行了分组分析。证据质量采用 GRADE 方法进行评估:在剔除重复和不符合条件的病例后,在获得的 1526 条记录中,有四篇文章被纳入了系统综述。结果表明,与安慰剂相比,使用葫芦巴能降低原发性痛经引起的疼痛强度(汇总结果 SMD:-2.21;95% CI:-3.26 至-1.17;Z:4.17;P 结论:葫芦巴能降低原发性痛经引起的疼痛强度:结果表明,葫芦巴对痛经疼痛强度的影响是非常不确定的。真正的效果很可能与效果估计值相差甚远。考虑到育龄妇女的健康和生活质量的重要性,以及研究证据的低质量,建议在这一领域进行方法更先进的临床试验。
The Effect of Fenugreek on the Severity of Dysmenorrhea: A Systematic Review and Meta-analysis.
Introduction: Dysmenorrhea is the most common periodic pain, which affects more than 50% of women with regular menstruation. Fenugreek is one of the medicinal plants with analgesic properties. This study aimed to determine the effect of fenugreek application in the severity of dysmenorrhea and its side effects in women with dysmenorrhea. PICO: Population: women with dysmenorrhea; Intervention: fenugreek; Comparison: control groups; and Outcome: reduction in the severity of dysmenorrhea and its side effects.
Methods: English database (PubMed, Cochrane Library, Scopus, and Web of Science) and Persian database [SID (Scientific Information Database) and Magiran] were used for research until February 11, 2023, using the keywords "Dysmenorrhea [Mesh]," "Foenum [Mesh]," "fenugreek [Mesh]," and "Trigonella [Mesh]." The reference list of the selected articles was also checked. The quality assessment was conducted through the Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0. The RevMan 5.3 software was used to analyze and report the data of the entered studies. Meta-analysis results were reported with the standardized mean difference (95% confidence interval). A subgroup analysis was performed based on the type of control groups. The quality of evidence was assessed using the GRADE approach.
Results: After removing duplicates and ineligible cases, four articles were included in the systematic review out of the 1526 records obtained. The results showed that the pain intensity caused by primary dysmenorrhea decreased with fenugreek compared to placebo (pooled result SMD: -2.21; 95% CI: -3.26 to -1.17; Z: 4.17; p <0.001). There was no significant difference between fenugreek with mefenamic acid (SMD: 0.05; 95% CI: -0.57 to 0.67; Z: 0.17; p = 0.86) and fenugreek with Chandrasura churna (SMD: 0.06; 95% CI: -0.56 to 0.68; Z: 0.19; p = 0.85). Bias, in terms of incomplete outcome data and selective reporting, was low risk in all studies, and the available evidence was low quality according to the GRADE approach.
Conclusion: The results showed that the effect of fenugreek on pain intensity in dysmenorrhea is highly uncertain. The true effect is likely to be substantially different from the estimate of effect. Regarding the importance of the health and quality of life of women of reproductive age and the low quality of evidence of the studies, clinical trials with stronger methodology are suggested in this field.